FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: A phase II study of safety, tolerability, and anti-inflammatory activity

Lehrer Graiwer Joshua; Parmanand Singh; Amr Abdelbaky; Esad Vucic; Magnus Korsgren; Amos Baruch; Jill Fredrickson; Nick Van Bruggen; Meina T. Tang; Bjorn Frendeus; James H.F. Rudd; Frank Hsieh; Christie M. Ballantyne; Brian Ghoshhajra; Robert S. Rosenson; Michael Koren; Eli M. Roth; Daniel A. Duprez; Zahi A. Fayad; Ahmed A. Tawakol

doi:10.1016/j.jcmg.2014.06.021

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: A phase II study of safety, tolerability, and anti-inflammatory activity

Lehrer Graiwer Joshua
, Parmanand Singh
, Amr Abdelbaky
, Esad Vucic
, Magnus Korsgren
, Amos Baruch
, Jill Fredrickson
, Nick Van Bruggen
, Meina T. Tang
, Bjorn Frendeus
, James H.F. Rudd
, Frank Hsieh
, Christie M. Ballantyne
, Brian Ghoshhajra
, Robert S. Rosenson
, Michael Koren
, Eli M. Roth
, Daniel A. Duprez
, Zahi A. Fayad
, Ahmed A. Tawakol

Research output: Contribution to journal › Letter › peer-review

85 Scopus citations

Original language	English
Pages (from-to)	493-494
Number of pages	2
Journal	JACC: Cardiovascular Imaging
Volume	8
Issue number	4
DOIs	https://doi.org/10.1016/j.jcmg.2014.06.021
State	Published - 1 Apr 2015
Externally published	Yes

Access to Document

10.1016/j.jcmg.2014.06.021

Cite this

Joshua, L. G., Singh, P., Abdelbaky, A., Vucic, E., Korsgren, M., Baruch, A., Fredrickson, J., Van Bruggen, N., Tang, M. T., Frendeus, B., Rudd, J. H. F., Hsieh, F., Ballantyne, C. M., Ghoshhajra, B., Rosenson, R. S., Koren, M., Roth, E. M., Duprez, D. A., Fayad, Z. A., & Tawakol, A. A. (2015). FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: A phase II study of safety, tolerability, and anti-inflammatory activity. JACC: Cardiovascular Imaging, 8(4), 493-494. https://doi.org/10.1016/j.jcmg.2014.06.021

@article{dc05fdff2359480888ace5fb2600d17e,

title = "FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: A phase II study of safety, tolerability, and anti-inflammatory activity",

author = "Joshua, \{Lehrer Graiwer\} and Parmanand Singh and Amr Abdelbaky and Esad Vucic and Magnus Korsgren and Amos Baruch and Jill Fredrickson and \{Van Bruggen\}, Nick and Tang, \{Meina T.\} and Bjorn Frendeus and Rudd, \{James H.F.\} and Frank Hsieh and Ballantyne, \{Christie M.\} and Brian Ghoshhajra and Rosenson, \{Robert S.\} and Michael Koren and Roth, \{Eli M.\} and Duprez, \{Daniel A.\} and Fayad, \{Zahi A.\} and Tawakol, \{Ahmed A.\}",

note = "Funding Information: Please note: This study was supported by Genentech, Inc . and BioInvent International AB . Dr. Lehrer-Graiwer is an employee of and holds stock in Global Blood Therapeutics. Dr. Singh was supported by a grant from the National Heart, Lung, and Blood Institute (5T32 HL076136). Dr. Korsgren was employed by BioInvent at the time of the study. Drs. Baruch and van Bruggen are employees of Genentech/Roche. Drs. Fredrickson and Tang are employees and stockholders of Genentech/Roche. Dr. Frendeus is an employee of BioInvent. Dr. Rudd is partly supported by the Cambridge NIHR Biomedical Research Centre . Dr. Ballantyne has received grant support and consulting fees from Genentech / Roche . Dr. Ghoshhajra has received consulting fees from Siemens. Dr. Rosenson has served on advisory boards for and has received grant support (institution) from F. Hoffman La Roche. Dr. Koren has received research grants from Roche . Dr. Roth has received consulting fees from Amgen, Sanofi, and Regeneron. Dr. Duprez has received research grants from Amgen , Sanofi , Regeneron , and Pfizer ; and has served on advisory boards for AstraZeneca and Novartis. Dr. Fayad has received grant support from Genentech / Roche . Dr. Tawakol has received grant support from Genentech / Roche ; and has received consulting fees from Genentech/Roche and BioInvent. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Lehrer-Graiwer and Singh contributed equally to this study and are co-first authors. ",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.jcmg.2014.06.021",

language = "English",

volume = "8",

pages = "493--494",

journal = "JACC: Cardiovascular Imaging",

issn = "1936-878X",

publisher = "Elsevier Inc.",

number = "4",

}

Joshua, LG, Singh, P, Abdelbaky, A, Vucic, E, Korsgren, M, Baruch, A, Fredrickson, J, Van Bruggen, N, Tang, MT, Frendeus, B, Rudd, JHF, Hsieh, F, Ballantyne, CM, Ghoshhajra, B, Rosenson, RS, Koren, M, Roth, EM, Duprez, DA, Fayad, ZA & Tawakol, AA 2015, 'FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: A phase II study of safety, tolerability, and anti-inflammatory activity', JACC: Cardiovascular Imaging, vol. 8, no. 4, pp. 493-494. https://doi.org/10.1016/j.jcmg.2014.06.021

TY - JOUR

T1 - FDG-PET imaging for oxidized LDL in stable atherosclerotic disease

T2 - A phase II study of safety, tolerability, and anti-inflammatory activity

AU - Joshua, Lehrer Graiwer

AU - Singh, Parmanand

AU - Abdelbaky, Amr

AU - Vucic, Esad

AU - Korsgren, Magnus

AU - Baruch, Amos

AU - Fredrickson, Jill

AU - Van Bruggen, Nick

AU - Tang, Meina T.

AU - Frendeus, Bjorn

AU - Rudd, James H.F.

AU - Hsieh, Frank

AU - Ballantyne, Christie M.

AU - Ghoshhajra, Brian

AU - Rosenson, Robert S.

AU - Koren, Michael

AU - Roth, Eli M.

AU - Duprez, Daniel A.

AU - Fayad, Zahi A.

AU - Tawakol, Ahmed A.

N1 - Funding Information: Please note: This study was supported by Genentech, Inc . and BioInvent International AB . Dr. Lehrer-Graiwer is an employee of and holds stock in Global Blood Therapeutics. Dr. Singh was supported by a grant from the National Heart, Lung, and Blood Institute (5T32 HL076136). Dr. Korsgren was employed by BioInvent at the time of the study. Drs. Baruch and van Bruggen are employees of Genentech/Roche. Drs. Fredrickson and Tang are employees and stockholders of Genentech/Roche. Dr. Frendeus is an employee of BioInvent. Dr. Rudd is partly supported by the Cambridge NIHR Biomedical Research Centre . Dr. Ballantyne has received grant support and consulting fees from Genentech / Roche . Dr. Ghoshhajra has received consulting fees from Siemens. Dr. Rosenson has served on advisory boards for and has received grant support (institution) from F. Hoffman La Roche. Dr. Koren has received research grants from Roche . Dr. Roth has received consulting fees from Amgen, Sanofi, and Regeneron. Dr. Duprez has received research grants from Amgen , Sanofi , Regeneron , and Pfizer ; and has served on advisory boards for AstraZeneca and Novartis. Dr. Fayad has received grant support from Genentech / Roche . Dr. Tawakol has received grant support from Genentech / Roche ; and has received consulting fees from Genentech/Roche and BioInvent. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Lehrer-Graiwer and Singh contributed equally to this study and are co-first authors.

PY - 2015/4/1

Y1 - 2015/4/1

UR - https://www.scopus.com/pages/publications/84928124939

U2 - 10.1016/j.jcmg.2014.06.021

DO - 10.1016/j.jcmg.2014.06.021

M3 - Letter

C2 - 25457756

AN - SCOPUS:84928124939

SN - 1936-878X

VL - 8

SP - 493

EP - 494

JO - JACC: Cardiovascular Imaging

JF - JACC: Cardiovascular Imaging

IS - 4

ER -